Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
certolizumab pegol (Cimzia®)
Reference No. 1713
Publication date:
31/10/2014
Appraisal information
certolizumab pegol (Cimzia®) 200 mg solution for injection
Company:
UCB Pharma Ltd
BNF category:
Musculoskeletal and joint diseases
NMG meeting date:
10/09/2014
AWMSG meeting date:
08/10/2014
Submission Type:
Full Submission
Status:
Superseded
Advice No:
3214
Ratification by Welsh Government:
30/10/2014
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA445) NICE GUIDANCE ISSUED MAY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
certolizumab pegol (Cimzia) 1713 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
certolizumab pegol (Cimzia) 1713 ASAR
Clinical Expert (CE) Summary
Download
certolizumab pegol (Cimzia) 1713 CE summary